ClinicalTrials.gg
RecruitingNCT07500714Updated Mar 30, 2026

Integrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine

An interventional study of Internet Cognitive-Behavioral Therapy and Sham treatment in Depression - Major Depressive Disorder, sponsored by National Science and Technology Council, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2025, registered Mar 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Depression with a site in Taiwan — 36 open to participants now, 43 under way, 3 of them phase 3. Depression · Taiwan.

Planned enrollment
50th of 141
100 · median 80
Started
2025
with 15 others
No phase
118 of 166
29 open now
Primary completion
2027-06
later than 21 of 42 live
Registered
148th of 166
by date

Among the 166 studies in Depression with a site in Taiwan, this one is the 50th largest by planned enrollment of the 141 interventional ones that give a count, is one of 16 that started in 2025, is one of 118 with no phase, reaches primary completion later than 21 of the 42 other live ones, and was the 148th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

36 of the 166 studies in Depression with a site in Taiwan are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Depression with a site in Taiwan, or all of them as a file.
02

Study summary

This project aims to integrate digital phenotyping and AI-driven iCBT into a comprehensive platform for MDD diagnosis and treatment in Taiwan. The study will explore dynamic, real-time behavioral and physiological markers to refine diagnostic classifications and optimize personalized therapeutic strategies.

03

Conditions studied

  • Depression - Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Aged 18-75 years
  • Diagnosis of major depressive disorder disorder (Based on Diagnostic Statistical Manual 5)
  • 21-item Hamilton Depression Scale (HAMD21)>17
  • No changes in current psychiatric treatment for depression (e.g., no treatment, antidepressant medication, psychotherapy, or non-invasive brain stimulation) within the past four weeks, and
  • Full competency to understand the study details and provide written

Exclusion criteria

Exclusion Criteria:

  • Scores of 5 ( Markedly ill), 6,(Severely ill), and 7 (Among the most extremely ill) according to the Clinical Global Impression Scale-Severity (CGI-S)
  • Psychotic disorders, bipolar affective disorder, a substance use disorders in the past 6 months, active suicidal or homicidal ideation (per assessment or HAMD>3)
  • Unstable or active medical illness.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    GPT-powered iCBT

    Behavioral: Internet Cognitive-Behavioral Therapy

  • Sham comparator
    Sham

    Behavioral: Sham treatment

Interventions

  • BehavioralInternet Cognitive-Behavioral Therapy

    GPT-powered iCBT the participants will receive 8 sessions (30 minutes per session)

    Also known as: iCBT

  • BehavioralSham treatment

    Sham (relaxation/supportive interaction) treatment at Day 2, 5, 9, 12, 16, 19, 23, 27.

06

What researchers measure

Primary outcomes

  1. Depression Severity

    Depression severity is measured by the 21-item Hamilton Rating Scale for Depression (HAM-D). A higher score indicates greater severity, a score of ≥18 indicates moderate to severe depression.

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

  2. Depression Severity

    Depression severity is measured by the 9-item Patient Health Questionnaire (PHQ-9). A score of ≥10 is the most common threshold used to identify individuals likely to have major depressive disorder.

    Time frame: Weeks 0, 1, 2, 4, 8,12, 16, 20, 24

  3. Stress Level

    Stress level is measured by the Life Events Perceived Stress (LEPS). A total score of ≥27 is widely recognized as the cut-off for high perceived stress.

    Time frame: Weeks 0, 1, 2, 4, 8,12, 16, 20, 24

  4. Quality of Life Assessment

    Quality of Life Assessment is measured by the EuroQol questionnaire (EQ-5D). The Index Score (usually 0 to 1), where 1.0 is full health, index scores below 0.6 are often characterized as representing low quality of life

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

Secondary outcomes

  1. Psychological well-being

    Psychological well-being is measured by the Brief Live Experience Questionnaire (BLEQ12). Score Range: 0-36; higher scores indicate greater general psychological well-being.

    Time frame: Weeks 0, 4

  2. Resilience Scale

    Resilience is measured by the Resilience Scale for Adults (RSA). The scale uses a 7-point semantic differential scale (e.g., ranging from "Difficult to accomplish" to "Possible to accomplish"), with a total score range of: 33 to 231.

    Time frame: Weeks 0, 4

  3. Potential traumatic experiences

    Resilience is measured by the Adverse Childhood Experiences-International Questionnaire. ACE Score (0-13): One point is given for each category of trauma experienced. The "Cut-off": A score of ≥4 is the widely recognized threshold where the risk of chronic disease, depression, and social problems increases significantly.

    Time frame: Weeks 0, 4

  4. Nutrition Assessment

    Nutrition Assessment is measured by the Taiwanese version of the Mini Nutrition Assessment (MNA). The MNA Long Form consists of 18 items with a maximum score of 30 points, where a score of 24 to 30 points indicates normal nutritional status, 17 to 23.5 points indicates a risk of malnutrition, and less than 17 points signifies that the individual is malnourished.

    Time frame: Weeks 0, 4

  5. Peripheral Neuropathy Symptom Assessment

    Peripheral Neuropathy Symptom is measured by the self-reported Neurotoxicity Rating Scale (NTRS)

    Time frame: Weeks 0, 4

  6. Physical Activity Level

    Continuous monitoring of daily physical activity via the Garmin Vívoactive 5 wearable device. Unit of Measure: number of steps per day. \<5,000 steps/day is often defined as "sedentary," while \>7,500 steps/day is "physically active"

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

  7. Heart Rate Variability (HRV)

    Continuous monitoring of the variation in time between consecutive heartbeats measured during rest using the Garmin Vívoactive 5. Unit of Measure: Root mean square of successive differences (RMSSD) in milliseconds (ms). Absolute Values (RMSSD): For healthy adults (ages 38-42), a normal range is typically 19-48 ms. Scores significantly below this (e.g., \<20 ms) are often used as a cut-off for high physiological stress or poor recovery.

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

  8. Sleep Patterns (Sleep Score)

    Continuous monitoring is measured using the Garmin Vívoactive 5. Garmin's internal "Sleep Score" (0-100) uses 60 as the threshold for "Poor" sleep. A higher score shows better results.

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

07

Study locations

1 of 1 sites recruiting
  • Mind Body Interface Research Center (MBI Lab & Care)
    Taichung, Taichung 404, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 30, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07500714
Lead sponsor
National Science and Technology Council, Taiwan
Responsible party
Kuan-Pin (Professor, National Science and Technology Council, Taiwan) — Principal investigator
First posted
Mar 30, 2026
Start date
Jun 1, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Kuan-Pin Su, MD, PhD.
Contact
cobol@cmu.edu.tw
04-22361230

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion